Literature DB >> 25677950

Hormone replacement therapy: who should be treated?

M Gambacciani1, M Levancini.   

Abstract

The last decade has been characterized by a careful review of the risks and benefits of hormone replacement therapy (HRT). Various types and doses as well as different combinations, may offer different advantages in different groups of women. Women with premature or early menopause may benefit from HRT, at least until the age at which natural menopause usually occurs. The most favorable benefits of HRT is in symptomatic younger women (50-59 years) within 10 years since menopause. Beside the effect on symptoms, these patients have additional benefits such as reduction in cardiovascular disease (CVD), osteoporotic fractures, and overall mortality. In older women low-dose or ultra-low-dose HRT may have a better safety profile than standard dose oral combinations. Currently, available evidence does not support the use of HRT for the sole osteoporosis or CVD and cognition decline prevention.

Entities:  

Mesh:

Year:  2015        PMID: 25677950

Source DB:  PubMed          Journal:  Minerva Ginecol        ISSN: 0026-4784


  3 in total

1.  Encapsulation of Mesenchymal Stem Cells in 3D Ovarian Cell Constructs Promotes Stable and Long-Term Hormone Secretion with Improved Physiological Outcomes in a Syngeneic Rat Model.

Authors:  Sivanandane Sittadjody; Kevin M Enck; Alexandra Wells; James J Yoo; Anthony Atala; Justin M Saul; Emmanuel C Opara
Journal:  Ann Biomed Eng       Date:  2019-07-31       Impact factor: 3.934

2.  Bergapten promotes bone marrow stromal cell differentiation into osteoblasts in vitro and in vivo.

Authors:  Ji-jie Xiao; Wen-ji Zhao; Xin-tao Zhang; Wen-long Zhao; Xiao-xia Wang; Shu-hui Yin; Fang Jiang; Yin-xia Zhao; Fang-ni Chen; Shao-lin Li
Journal:  Mol Cell Biochem       Date:  2015-07-19       Impact factor: 3.396

3.  Interaction between cardiovascular autonomic control and sex hormones in perimenopausal women under menopausal hormone therapy.

Authors:  Anton R Kiselev; Irina W Neufeld; Irina V Bobyleva; Mikhail D Prokhorov; Anatoly S Karavaev
Journal:  Cardiovasc Endocrinol Metab       Date:  2018-08-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.